News
Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...
GLP-1 weight loss patches are everywhere but do they actually work as these trendy patches promise Ozempic-like results ...
The country’s Medicines and Healthcare products Regulatory Agency’s Yellow Card scheme, the UK’s official system for ...
CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...
MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...
A GLP-1/glucagon dual agonist conferred weight loss of up to 12.55% at 32 weeks for adults with overweight or obesity, ...
Study finds the GLP-1 drug liraglutide reduced migraine days by almost 50% in patients with obesity, with quality of life ...
With new leadership and a Nasdaq relisting plan, the iconic brand is betting on women’s health and weight loss drugs to stage ...
1d
News-Medical.Net on MSNTirzepatide tops the charts for blood sugar and weight loss in type 2 diabetesA large network meta-analysis ranked eight GLP-1 receptor agonists for glycemic, weight, and safety outcomes in adults with ...
1d
Everyday Health on MSN9 Signs Your Compounded GLP-1 Supplier Is ShadySome online pharmacies sell semaglutide and tirzepatide that are ineffective, unsafe, or an outright scam. Here’s how to find ...
The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.
This is Prime Therapeutics’ latest research into GLP-1s and the long term impact of taking the medication. In October of last ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results